Investigating the effect of early montelukast use on the need for hospitalization, duration of hospitalization and clinical symptoms in children aged 2 to 15 years with the diagnosis of Hyperreactiv Airway Disease (HRAD)
Phase 3
Recruiting
- Conditions
- Hyperreactiv airway disease.Respiratory conditions due to unspecified external agentJ70.9
- Registration Number
- IRCT20230930059560N1
- Lead Sponsor
- Shahre-kord University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Children with airway hyperreactivity between 2 years and 15 years who have not recently used systemic or inhaled corticosteroids and are not known to have asthma.
Absence of serious diseases that interfere with the research results (such as severe heart or lung diseases).
Has not recently used long-term bronchodilators or theophylline.
Exclusion Criteria
patient with known asthma
Other diagnoses such as pneumonia are relevant
Recent treatment with systemic or inhaled corticosteroids
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eed to be hospitalized. Timepoint: At the beginning of the study and then every 3 days until the end of 2 weeks. Method of measurement: Clinical examination: pulmonary auscultation with a stethoscope, measurement of arterial oxygen with a pulse oximeter.;Duration of hospitalization. Timepoint: From the time of admission to the hospital until discharge on a daily basis. Method of measurement: Counting the number of days of hospitalization.
- Secondary Outcome Measures
Name Time Method